"You look for overall survival in the marker-positive group and overall survival for the whole group."

– John Heymach of the University of Texas M.D. Anderson Cancer Center, discussing work on cancer biomarkers, "New trial designs could solve biomarker dilemma in cancer," pp. 1, 7.